These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33070660)

  • 1. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
    Kim GP; Surinach A; Corvino FA; Cockrum P; Belanger B; Abushahin L
    Future Oncol; 2021 Feb; 17(6):675-688. PubMed ID: 33070660
    [No Abstract]   [Full Text] [Related]  

  • 2. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
    Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
    Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
    Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
    Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA
    J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
    Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
    Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence.
    Gupta A; De Jesus-Acosta A; Le D; Pishvaian M; Zaidi N; Zheng L; Laheru D
    Cancer; 2024 Nov; 130(21):3734-3744. PubMed ID: 38985839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
    Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
    Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
    Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
    Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
    Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
    Bockorny B; Macarulla T; Semenisty V; Borazanci E; Feliu J; Ponz-Sarvise M; Abad DG; Oberstein P; Alistar A; Muñoz A; Geva R; Guillén-Ponce C; Fernandez MS; Peled A; Chaney M; Gliko-Kabir I; Shemesh-Darvish L; Ickowicz D; Sorani E; Kadosh S; Vainstein-Haras A; Hidalgo M
    Clin Cancer Res; 2021 Sep; 27(18):5020-5027. PubMed ID: 34253578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
    Kodama T; Imajima T; Shimokawa M; Otsuka T; Kawahira M; Nakazawa J; Hori T; Shibuki T; Arima S; Ido A; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Sakai K; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Shirakawa T; Mizuta T; Mitsugi K
    Sci Rep; 2024 May; 14(1):12422. PubMed ID: 38816500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
    Salvia R; Malleo G; Maggino L; Milella M; Bassi C
    Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
    [No Abstract]   [Full Text] [Related]  

  • 18. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
    Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
    Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
    [No Abstract]   [Full Text] [Related]  

  • 20. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.